Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.47 |
| ▸ | LOX | P28300 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 13/20 | 0.44 |
| ▸ | FLT1 | P17948 | 12/20 | 0.44 |
| ▸ | PDGFRB | P09619 | 6/20 | 0.44 |
| ▸ | KIT | P10721 | 5/20 | 0.44 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.41 |
| ▸ | CIT | O14578 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | HLA-A | P04439 | 1/20 | 0.38 |
| ▸ | CSF1R | P07333 | 1/20 | 0.38 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.38 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.38 |
| ▸ | FLT4 | P35916 | 1/20 | 0.38 |
| ▸ | FRK | P42685 | 1/20 | 0.38 |
| ▸ | CDK8 | P49336 | 1/20 | 0.38 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.38 |
| ▸ | STK3 | Q13188 | 1/20 | 0.38 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4814035 | 0.80 | FLT1 (0.65) | KDRFLT1PDGFRBKITKCNQ2 | |
| SCHEMBL29841352 | 0.80 | FLT1 (0.65) | KDRFLT1PDGFRBKITKCNQ2 | |
| SCHEMBL26907246 | 0.76 | LOX (0.47) | LOXL2LOXKDRFLT1PDGFRB | |
| SCHEMBL905518 | 0.75 | FLT1 (0.59) | KDRFLT1PDGFRBKITCIT | |
| SCHEMBL30773496 | 0.75 | FLT1 (0.59) | KDRFLT1PDGFRBKITCIT | |
| SCHEMBL26907276 | 0.74 | PARP1 (0.58) | — | |
| SCHEMBL2310333 | 0.73 | NPSR1 (0.56) | KDRFLT1PDGFRBKITCIT | |
| SCHEMBL3610027 | 0.72 | KDR (0.43) | KDRFLT1PDGFRBKITCIT | |
| SCHEMBL7115917 | 0.71 | SMO (0.44) | KDRFLT1PDGFRBKITCIT | |
| SCHEMBL24611361 | 0.69 | LOXL2 (0.54) | LOXL2LOXKCNQ2TYMSGPR52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174651-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED | 2024-05-30 | — | — | US | disclosed |
| CN-117355303-A | Compounds and their use for the treatment of neurodegenerative, degenerative and metabolic disorders | 佛罗里达大学研究基金会公司 | 2024-01-05 | — | — | CN | disclosed |
| EP-4284372-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | University of Florida Research Foundation, Incorporated (US) | 2023-12-06 | — | — | EP | disclosed |
| WO-2022165173-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174651-A1 | COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE, DEGENERATIVE AND METABOLIC DISORDERS | NLN, OAT, PC | LOXL2 1430/4885LOX 497/4885KDR 4812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.